These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24091919)

  • 41. Japan sets up gene therapy panel.
    Swinbanks D
    Nature; 1994 Feb; 367(6463):502. PubMed ID: 8107816
    [No Abstract]   [Full Text] [Related]  

  • 42. The modern therapy of systemic vasculitides: perspectives and challenges.
    Novikov PI; Zykova AS; Moiseev SV
    Ter Arkh; 2018 Feb; 90(1):76-85. PubMed ID: 30701763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Usefulness of vasculitis biomarkers in the era of the personalized medicine.
    Csernok E; Hellmich B
    Autoimmun Rev; 2020 May; 19(5):102514. PubMed ID: 32171919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trials on systemic necrotizing vasculitides.
    Guillevin L
    Presse Med; 2010 Jun; 39(6):653-9. PubMed ID: 20206461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. National Institutes of Health. Points to consider in the design and submission of human somatic-cell gene therapy protocols. Human Gene Therapy Subcommittee, NIH Recombinant DNA Advisory Committee. Adopted September 29, 1986.
    Recomb DNA Tech Bull; 1986 Dec; 9(4):221-42. PubMed ID: 3469693
    [No Abstract]   [Full Text] [Related]  

  • 46. [Intractable vasculitis syndromes--incidence and epidemiology].
    Tanabe T
    Nihon Rinsho; 1994 Aug; 52(8):1987-91. PubMed ID: 7933574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatric Vasculitis.
    Singh-Grewal D; Durkan AM
    Indian J Pediatr; 2016 Feb; 83(2):156-62. PubMed ID: 26365154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. APS Advises USDA on Ways to Reduce Regulatory Burden.
    Physiologist; 2016 Jul; 59(4):193. PubMed ID: 28333421
    [No Abstract]   [Full Text] [Related]  

  • 49. Neurologic presentations of systemic vasculitides.
    Minagar A; Fowler M; Harris MK; Jaffe SL
    Neurol Clin; 2010 Feb; 28(1):171-84. PubMed ID: 19932380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Network for Clinical Stroke Trials (NeCST) for the Next Stroke Researchers in Japan.
    Toyoda K; Yamamoto H; Koga M
    Stroke; 2016 Feb; 47(2):304-5. PubMed ID: 26715456
    [No Abstract]   [Full Text] [Related]  

  • 51. Minutes of meeting of the Recombinant DNA Advisory Committee, 30 Mar 1990.
    U.S. National Institutes of Health. Recombinant DNA Advisory Committee
    Hum Gene Ther; 1990; 1(4):493-501. PubMed ID: 11642816
    [No Abstract]   [Full Text] [Related]  

  • 52. Petition to amend the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules to establish a Public Policy Advisory Committee. Foundation on Economic Trends, September 18, 1990.
    Hum Gene Ther; 1991; 2(2):131-4. PubMed ID: 1911933
    [No Abstract]   [Full Text] [Related]  

  • 53. [Multicenter study of causes of death in systemic lupus erythematosus-a report from the Subcommittee for Development of Therapy, the Research Committee for Autoimmune Diseases Supported by the Ministry of Health and Welfare].
    Ichikawa Y; Tsunematsu T; Yokohari R; Tanimoto K; Sakane T; Yoshida H; Kano S; Sawada S; Hashimoto H; Nagasawa T
    Ryumachi; 1985 Sep; 25(4):258-64. PubMed ID: 4081905
    [No Abstract]   [Full Text] [Related]  

  • 54. Minutes of meeting of the Human Gene Therapy Subcommittee, 30 Mar 1990.
    U.S. National Institutes of Health. Recombinant DNA Advisory Committee. Human Gene Therapy Subcommitttee
    Hum Gene Ther; 1990; 1(4):481-91. PubMed ID: 11642815
    [No Abstract]   [Full Text] [Related]  

  • 55. Cutaneous and systemic vasculitides in dermatology: a histological perspective.
    Alberti-Violetti S; Berti E; Marzano AV
    G Ital Dermatol Venereol; 2018 Apr; 153(2):185-193. PubMed ID: 29368866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant DNA Advisory Committee: minutes of meeting, 10-11 Feb 1992.
    U.S. National Institutes of Health. Recombinant DNA Advisory Committee
    Hum Gene Ther; 1992 Oct; 3(5):563-91. PubMed ID: 11643034
    [No Abstract]   [Full Text] [Related]  

  • 57. Human Gene Therapy Subcommittee: minutes of meeting, 5 Apr 1991.
    U.S. National Institutes of Health. Recombinant DNA Advisory Committee. Human Gene Therapy Subcommittee
    Hum Gene Ther; 1992 Apr; 3(2):233-48. PubMed ID: 11643022
    [No Abstract]   [Full Text] [Related]  

  • 58. Minutes of meeting, 7-8 Oct 1991.
    U.S. National Institutes of Health. Recombinant DNA Advisory Committee
    Hum Gene Ther; 1992 Jun; 3(3):341-56. PubMed ID: 11643011
    [No Abstract]   [Full Text] [Related]  

  • 59. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
    Hellmich B; Flossmann O; Gross WL; Bacon P; Cohen-Tervaert JW; Guillevin L; Jayne D; Mahr A; Merkel PA; Raspe H; Scott DG; Witter J; Yazici H; Luqmani RA
    Ann Rheum Dis; 2007 May; 66(5):605-17. PubMed ID: 17170053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment criteria for vitamin D deficiency/insufficiency in Japan - proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion].
    Okazaki R; Ozono K; Fukumoto S; Inoue D; Yamauchi M; Minagawa M; Michigami T; Takeuchi Y; Matsumoto T; Sugimoto T
    Endocr J; 2017 Jan; 64(1):1-6. PubMed ID: 28003569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.